Alprostadil

證據等級: L5

預測適應症: 10 個

Alprostadil: From Ductus-Dependent Congenital Heart Disease to Atypical Coarctation of Aorta

One-Sentence Summary

Alprostadil (Prostaglandin E1, PGE1) is a synthetic prostaglandin used in neonates to maintain patency of the ductus arteriosus in ductus-dependent congenital heart disease, serving as the cornerstone of preoperative stabilisation in this setting. The TxGNN model predicts it may be effective for Atypical Coarctation of Aorta, with 1 clinical trial and 2 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Ductus-dependent congenital heart disease — PDA maintenance (detailed regulatory text not available in current dataset)
Predicted New Indication	Atypical Coarctation of Aorta
TxGNN Prediction Score	99.99%
Evidence Level	L4
Malaysia Market Status	✓ Marketed
Number of Registrations	2
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, Alprostadil is a synthetic analogue of Prostaglandin E1 (PGE1), a naturally occurring eicosanoid derived from arachidonic acid. Its principal pharmacological actions include arterial vasodilation, smooth muscle relaxation, inhibition of platelet aggregation, and anti-inflammatory effects (including suppression of TNF-α and IL-6 production). At the molecular level, PGE1 acts via EP receptors to elevate intracellular cyclic AMP (cAMP), triggering relaxation of vascular smooth muscle — particularly in the ductus arteriosus wall, which forms the basis of its established neonatal use.

Atypical coarctation of the aorta encompasses cases driven not by simple structural narrowing, but by inflammatory vasculitis — most notably Takayasu’s arteritis. In the acute inflammatory phase of Takayasu’s disease, active vessel wall inflammation leads to stenosis and compromised distal perfusion. Alprostadil’s anti-inflammatory and vasodilatory properties are theoretically applicable here: by reducing vascular wall inflammation and improving microvascular perfusion, it may help bridge the patient toward definitive immunosuppressive therapy or surgical repair. If cardiac failure coexists (as commonly seen in paediatric Takayasu’s), Alprostadil’s afterload-reducing effect may provide additional haemodynamic support.

The mechanistic link is indirect but biologically plausible. It does not represent a direct overlap with the drug’s approved PDA indication, but rather an extension of its vascular pharmacology into an inflammatory aortic disease context. Robust clinical validation in this specific indication is currently absent, limiting this to a hypothesis-generating stage.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02042092	N/A	Completed	39	Cross-sectional comparison of CDUS vs MRA imaging in systemic large vessel vasculitis (aorta, carotid, subclavian, vertebral, axillary, and temporal arteries). This is a diagnostic imaging study — it does not test Alprostadil as a therapeutic intervention and provides no direct drug efficacy evidence.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30172258	2018	Case Report	Journal of Medical Case Reports	Continuous infusion of lipo-PGE1 (Alprostadil) in an 11-month-old infant with Takayasu’s arteritis complicated by heart failure. Demonstrates the feasibility and clinical rationale of Alprostadil use in paediatric inflammatory aortic disease with haemodynamic compromise; corticosteroids remain the primary treatment for vascular damage prevention.
9506883	1998	Case Report	Scandinavian Journal of Rheumatology	Aortitis syndrome (Takayasu’s arteritis) presenting with cataract as the initial finding, with elevated serum VEGF prior to prednisolone treatment. Provides disease context and highlights the role of inflammatory cytokines in aortitis; does not directly evaluate Alprostadil therapy.

Malaysia Market Information

Detailed product registration information — including license numbers, product names, dosage forms, and approved indication text — was not available in the current regulatory dataset. The drug is confirmed as marketed in Malaysia with 2 registered products. To retrieve complete registration details, please consult the National Pharmaceutical Regulatory Agency (NPRA) database directly.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence base for Alprostadil specifically in atypical (inflammatory) coarctation of the aorta is limited to a single directly relevant case report and one non-interventional imaging study. While the biological rationale is plausible given PGE1’s vasodilatory and anti-inflammatory profile, the absence of controlled clinical data means this indication cannot yet proceed beyond the research question stage. Notably, the second-ranked prediction (Aortic Malformation, L3 evidence, “Proceed with Guardrails”) carries a substantially richer evidence base — including a direct Alprostadil trial (NCT04054115) and 20 publications — and may represent a more actionable near-term repurposing pathway.

To proceed, the following is needed:

Mechanism of action data (MOA) from DrugBank to formally characterise receptor targets and downstream signalling relevant to inflammatory vascular disease
Full Malaysia regulatory data: package insert warnings, contraindications, and approved indication text from the NPRA portal (currently a Blocking data gap — DG001)
Prospective case series or pilot investigator-initiated study in paediatric Takayasu’s arteritis with aortic involvement evaluating Alprostadil as adjunctive anti-inflammatory therapy
Systematic review of PGE1 use in large vessel vasculitis in the existing literature to consolidate scattered case-level evidence
Clarification of the route and dose applicable to this indication (IV infusion as in PDA use vs. alternate routes) given current route compatibility data is pending
Parallel evaluation of the Aortic Malformation indication (Rank 2, L3), which shares the same mechanistic foundation but has broader and better-characterised clinical evidence supporting development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.